generation run 2026-05-13
63 min completedmodel pipeline-v5plan not recordedrun/46ea70dc…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- safety_data_unverified
- sparse_evidence
- contradictory_sources
- structural_inference
- contaminant_data_absent
Reproduce
- inputs
- 19 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
28 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | WebSearch | Nymphaea caerulea legal status FDA DEA scheduling 2024 2025 | 10 | 3 | Confirmed legal status across key US jurisdictions |
| 2 | PubChem | apomorphine | 1 | 1 | Confirmed chemical identity of second key alkaloid |
| 3 | PubMed | Nymphaea caerulea chemical composition phytochemistry | 1 | 1 | Primary phytochemical characterization of N. caerulea flowers |
| 4 | PubChem | nuciferine | 1 | 1 | Confirmed chemical identity of primary alkaloid |
| 5 | PubMed | Nymphaea caerulea apomorphine nuciferine psychoactive | 2 | 2 | Direct analyses of blue lotus psychoactive alkaloid content |
| 6 | Erowid | blue lotus lotus legal status Nymphaea caerulea | 3 | 2 | Best available legal status data by jurisdiction |
| 7 | PubMed | Nymphaea caerulea alkaloids pharmacology | 4 | 4 | All relevant to blue lotus alkaloid profile and pharmacology |
| 8 | OpenAlex | Nymphaea caerulea ancient Egypt sacred lotus ritual use history | 10 | 3 | Archaeological and historical evidence for ritual use |
| 9 | OpenAlex | Nymphaea caerulea blue lotus pharmacology alkaloids | 10 | 6 | Key reviews on botanical pharmacology and historical/archaeological use |
| 10 | PubMed · absence | Nymphaea caerulea blue lotus ethnobotany traditional use | 0 | — | — |
| 11 | WebSearch | blue lotus legal status UK Europe Australia Canada 2024 2025 | 10 | 5 | International legal status survey |
| 12 | OPSS/DoD | blue lotus military prohibited safety risks | 1 | 2 | Regulatory prohibition data and documented adverse effects |
| 13 | WebSearch | blue lotus Nymphaea caerulea drug test detection urine screen | 10 | 2 | Drug test detectability data |
| 14 | PubMed | blue lotus toxicity case series military adverse effects | 1 | 1 | Primary safety data: adverse events and clinical management |
| 15 | WebSearch | Nymphaea caerulea apomorphine presence absence controversy research | 10 | 1 | Critical uncertainty about whether apomorphine actually occurs naturally in N. caerulea |
| 16 | PubMed | Identification and characterization of potent CYP2D6 inhibitors in lotus leaves | 1 | 1 | Mechanistic basis for herb-drug interactions via CYP inhibition |
| 17 | PMC | Nymphaea cults ancient Egypt New World pharmacology | 1 | 1 | Key historical/ethnobotanical review linking ancient Egyptian and Maya lotus cults to pharmacology |
| 18 | PubMed | nuciferine pharmacokinetics absorption distribution metabolism | 3 | 2 | Direct pharmacokinetic characterization of nuciferine |
| 19 | Multiple sources | Apomorphine presence in Nymphaea caerulea - cross-referencing Poklis 2017 vs Dosoky 2023 | 2 | 1 | Critical uncertainty flagged for generation agent |
| 20 | PubMed · absence | nuciferine reproductive toxicity embryotoxicity pregnancy | 0 | — | — |
| 21 | WebSearch | blue lotus Russia Poland Latvia scheduling controlled substances | 10 | 3 | Additional international scheduling data |
| 22 | PubMed | Nymphaea lotus anxiolytic antidepressant mice | 1 | 1 | Closely related species providing animal model evidence for sedative/anxiolytic effects |
| 23 | PubMed · absence | Nymphaea lotus caerulea LD50 acute toxicity rodent | 0 | — | — |
| 24 | UC Berkeley | Berkeley blue lotus research chemical identity | 1 | 1 | Important adulteration/misidentification concern for commercial products |
| 25 | OpenAlex | nuciferine serotonin 5-HT2A dopamine receptor mechanism in vivo | 4 | 2 | Confirms comprehensive receptor profile of nuciferine |
| 26 | POWO / Kew Science | Nymphaea caerulea POWO taxonomy | 1 | 1 | Authoritative taxonomy |
| 27 | ClinicalTrials.gov | Nymphaea caerulea blue lotus | 1 | — | No relevant clinical trials found |
| 28 | PubChem | nuciferine CID 10146 and apomorphine CID 6005 | 2 | 2 | Chemical identity verification for both key alkaloids |
45 claims by section — every cited sentence, checked against its source
alkaloid-profile9 · 6 ok
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Poklis and colleagues detected nuciferine in all five samples analyzed (four commercial products and one confiscated resin). The resin contained 4,300 ng/g nuciferine.supported
Nuciferine detected in all 5 samples; apomorphine in 2/5. Confiscated resin contained 4300 ng/g nuciferine, no apomorphine. 02791072.2017.1290304
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Poklis and colleagues detected apomorphine in two of five commercial samples, while Dosoky and colleagues found it virtually absent from authenticated extracts, noting that its natural occurrence in the plant "is doubtful on chemical grounds"supported
Apomorphine and nuciferine virtually absent from authentic extracts. molecules28207014
Agnihotri and colleagues isolated 20 constituents from N. caerulea flowers — no aporphine alkaloids were detected in this studysupported
20 constituents isolated from N. caerulea flowers including myricetin, quercetin, kaempferol glycosides, flavonoids, sterols, phenolic acids. j.phytochem.2008.04.009
Dosoky and colleagues characterized authenticated extracts as consisting primarily of aliphatic hydrocarbons, aromatic alcohols, fatty acids, phenyl derivatives, diterpenoids, and phytosterols.supported
Extracts were mixture of aliphatic hydrocarbons, aromatic alcohols, fatty acids, phenyl derivatives, diterpenoids, phytosterols, and stigmastanes. molecules28207014
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
He and colleagues identified 48 compounds including 26 alkaloids from N. nucifera leaves, petals, and seeds — with nuciferine, armepavine, asimilobine, and luteolin as key sleep-relevant componentssupported
48 compounds identified including 26 alkaloids. Armepavine, asimilobine, nuciferine, and luteolin identified as key sleep-related components. cbdv.202402788
The contrast between near-absent alkaloids in authenticated aromatic extracts and measurable nuciferine in concentrated resin indicates that processing method substantially determines psychoactive alkaloid availabilitysupported
Apomorphine and nuciferine virtually absent from authentic extracts. molecules28207014
history8 · 3 ok
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Poklis and colleagues published among the first clinical-context reports in Western medical literature in 2017, analyzing blue lotus resin used in electronic cigarettessupported
Blue lotus resin and 4 commercial products analyzed... Resin aerosolized with RDA e-cigarette. 02791072.2017.1290304
Published pharmacological research has concentrated on isolated nuciferine — predominantly sourced from Nelumbo nucifera leaf — investigating its antipsychotic-like properties and anti-obesity potential, rather than on whole N. caerulea preparations.supported
Nuciferine characterized as antagonist at 5-HT2A, 5-HT2C, 5-HT2B... antipsychotic-like profile without catalepsy. journal.pone.0150602
Published pharmacological research has concentrated on isolated nuciferine — predominantly sourced from Nelumbo nucifera leaf — investigating its antipsychotic-like properties and anti-obesity potential, rather than on whole N. caerulea preparations.supported
Review of nuciferine anti-obesity, anti-dyslipidemia, anti-hyperglycemic, anti-inflammatory effects; neural receptor affinity; PK, pharmaceutics, and security data. j.phrs.2021.106002
neuroscience7 · 4 ok
Oral bioavailability of nuciferine is approximately 3.8–4.2% in rats (tested at 2.0, 5.0, and 10.0 mg/kg oral doses versus 0.2 mg/kg IV), with one-compartmental pharmacokinetics characterized by rapid distribution, extensive tissue uptake, and poor systemic absorptionsupported
Nuciferine oral bioavailability 3.8-4.2% in rats. One-compartmental PK: rapid distribution, extensive tissue uptake, poor systemic absorption. j.jchromb.2014.04.038
Farrell and colleagues characterized nuciferine's receptor binding profile through the NIMH Psychoactive Drug Screening Program:supported
Nuciferine characterized as antagonist at 5-HT2A, 5-HT2C, 5-HT2B; inverse agonist at 5-HT7; partial agonist at D2, D5, 5-HT6; agonist at 5-HT1A and D4; inhibits dopamine transporter. journal.pone.0150602
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Nuciferine distributes to brain, liver, and adipose tissue after IV administration, confirming CNS penetrationsupported
Distributed to brain, liver, and adipose tissue after IV administration. j.jchromb.2014.04.038
Claim in neuroscience — inconclusiveinconclusiveworking →
Wang and colleagues further characterized excretion pathways via LC-MS/MS in rats.supported
Characterization of nuciferine pharmacokinetics, tissue distribution, bioavailability, and excretion using LC/MS/MS in rats. 03639045.2018.1483399
safety7 · 6 ok
Schimpf and colleagues documented five active-duty military patients presenting to the emergency department with altered mental status after blue lotus use: four after vaping resin or extract and one after consuming an infused beveragesupported
Case series of 5 active-duty patients presenting to emergency department with altered mental status after blue lotus use: 4 after vaping, 1 after infused beverage. usab328
Species misidentification and substitution: Dosoky and colleagues found that eleven commercial products did not resemble authenticated N. caerulea extracts in chemical composition or aromasupported
Six authentic N. caerulea extracts and eleven commercial products analyzed by GC-MS. molecules28207014
Blue lotus alkaloids (nuciferine, apomorphine) are not detectable on standard 5-, 10-, or 12-panel urine drug screenssupported
Blue lotus not detectable on standard urine drug screens. usab328
Dose-dependent perceptual disturbances, hallucinations, and confusion have been documented at high doses or via inhaled preparationspartially supported
Symptoms included sedation and perceptual disturbances. All managed with supportive measures. usab328
Nuciferine's 5-HT2A antagonism theoretically suggests low psychotomimetic risk relative to 5-HT2A agonists, but this inference applies to isolated nuciferine under controlled conditions and cannot be generalized to uncharacterized commercial preparations that may contain synthetic adulterantssupported
Nuciferine characterized as antagonist at 5-HT2A, 5-HT2C, 5-HT2B... Blocked head-twitch responses, substituted for clozapine, antipsychotic-like profile without catalepsy. journal.pone.0150602
Nelumbo nucifera leaf extract — which shares nuciferine with N. caerulea — contains potent in vitro CYP2D6 inhibitors, along with inhibitory activity on CYP2C9, CYP2C19, CYP2E1, and CYP3A4supported
Lotus leaf alcoholic extract assessed for inhibitory effects on CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 in vitro. Identified potent CYP2D6 inhibitors in lotus leaves (Nelumbo nucifera). j.jep.2014.02.014
Claim in safety — inconclusiveinconclusiveworking →
summary7 · 5 ok
Classified as a depressant and oneirogen, its psychoactive profile is attributed primarily to the aporphine alkaloid nuciferine, though published analytical data on authenticated plant material show only trace alkaloid concentrationssupported
Apomorphine and nuciferine virtually absent from authentic extracts. molecules28207014
Claim in summary — inconclusiveinconclusiveworking →
Nuciferine acts as an antagonist at 5-HT2A, 5-HT2B, and 5-HT2C receptors; an agonist at 5-HT1A and D4 receptors; a partial agonist at D2 and D5; and an inhibitor of the dopamine transporter — a profile described as similar to atypical antipsychoticssupported
Nuciferine characterized as antagonist at 5-HT2A, 5-HT2C, 5-HT2B; inverse agonist at 5-HT7; partial agonist at D2, D5, 5-HT6; agonist at 5-HT1A and D4; inhibits dopamine transporter. Blocked head-twitch responses, substituted for clozapine, antipsychotic-like profile without catalepsy. journal.pone.0150602
Oral bioavailability is approximately 3.8–4.2% in rats; no human pharmacokinetic data have been publishedsupported
Nuciferine oral bioavailability 3.8-4.2% in rats. j.jchromb.2014.04.038
The natural occurrence of apomorphine in this plant is chemically contested, with recent analytical work finding it virtually absent from authenticated extracts.supported
Apomorphine and nuciferine virtually absent from authentic extracts. molecules28207014
A clinical case series documented five patients with sedation and perceptual disturbances after blue lotus use, all recovering with supportive caresupported
Case series of 5 active-duty patients presenting to emergency department with altered mental status after blue lotus use... Symptoms included sedation and perceptual disturbances. All managed with supportive measures. usab328
Claim in summary — not_supportednot supportedworking →
preparations6 · 3 ok
Claim in preparations — inconclusiveinconclusiveworking →
One patient in the Schimpf case series presented after consuming a blue lotus infused beverage.supported
4 after vaping, 1 after infused beverage. usab328
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Sublingual administration bypasses first-pass hepatic metabolism, which is relevant given nuciferine's poor oral bioavailability in ratssupported
Nuciferine oral bioavailability 3.8-4.2% in rats... poor systemic absorption. j.jchromb.2014.04.038
Poklis and colleagues analyzed a confiscated resin aerosolized via this method, detecting 4,300 ng/g nuciferinesupported
Confiscated resin contained 4300 ng/g nuciferine, no apomorphine. Resin aerosolized with RDA e-cigarette. 02791072.2017.1290304
botanical-overview1 · 1 ok
Dosoky and colleagues found that eleven commercial products sold as blue lotus did not resemble authenticated N. caerulea extracts in aroma or chemical compositionsupported
Six authentic N. caerulea extracts and eleven commercial products analyzed by GC-MS. molecules28207014